AI assistant
Dechra Pharmaceuticals PLC — Director's Dealing 2019
Sep 18, 2019
4797_dirs_2019-09-18_25581991-e213-4984-842f-f85b115f4d86.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7894M
Dechra Pharmaceuticals PLC
18 September 2019
18 September 2019
Dechra Pharmaceuticals PLC
Notification of Transactions by Persons Discharging Managerial Responsibilities
On 17 September 2019, Dechra Pharmaceuticals PLC was notified by Directors of the Company and Persons Discharging Managerial Responsibilities that they had completed the sale of part of their beneficial interest in Dechra.
Ian Page, Executive Director and Tony Rice, Non-Executive Chairman, have sold 200,000 ordinary shares and 20,000 ordinary shares respectively in the Company to satisfy long term personal financial planning considerations and widen their investment portfolios. The shares have been placed in the market with investors. Following these transactions, Ian Page will continue to retain a beneficial holding of 586,650 which represents 0.571% and Tony Rice, 20,000 representing 0.019% of the current issued share capital in the Company.
The Notification of Dealing Forms set out below are provided in accordance with Article 19.3 of MAR.
Notification of Dealing Form:
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director | |
| b) | Initial notification/amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Sale of Shares | |
| c) | Price(s) and volumes(s) | Price(s) £29.1695 |
Volume(s) 200,000 |
| d) | Aggregated information -Aggregate volume - Price - Total |
200,000 £29.1695 £5,833,900 |
|
| e) | Date of the transaction | 17 September 2019 | |
| f) | Place of the transaction | London Stock Exchange |
Notification of Dealing Form:
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Tony Rice | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director | |
| b) | Initial notification/amendment | Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Sale of Shares | |
| c) | Price(s) and volumes(s) | Price(s) £29.09968 |
Volume(s) 20,000 |
| d) | Aggregated information -Aggregate volume - Price - Total |
20,000 £29.09968 £581,993.60 |
|
| e) | Date of the transaction | 17 September 2019 | |
| f) | Place of the transaction | London Stock Exchange |
| Enquiries: | |
| Dechra Pharmaceuticals PLC | |
| Ishbel Macpherson, Senior Independent Director | Office: +44 (0) 1606 814 730 |
| Ian Page, Chief Executive Officer | Office: +44 (0) 1606 814 730 |
| Paul Sandland, Acting Chief Financial Officer e-mail: [email protected] |
Office: +44 (0) 1606 814 730 |
| TooleyStreet Communications Ltd | |
| Fiona Tooley, Director e-mail: [email protected] |
Office: +44 (0) 121 309 0099 Mobile: +44 (0) 7785 703 523 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHSFMSAAFUSEEU